Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 3, 2009, Pages 304-325

  Tietze, Lutz F ^a   Krewer, Birgit ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

ADEPT; Anti tumour agents; CC 1065; Duocarmycins; PMT; Prodrugs; Targeted cancer therapy

Indexed keywords

BETA GALACTOSIDASE; CARMUSTINE; CYTOTOXIC AGENT; DOXORUBICIN; DU 257; DUOCARMYCIN DERIVATIVE; MELPHALAN; PRODRUG; RACHELMYCIN; RACHELMYCIN DERIVATIVE; UNCLASSIFIED DRUG; YW 242;

CANCER GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CYTOTOXICITY TEST; DNA ALKYLATION; DRUG CONJUGATION; DRUG DNA BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; IC 50; LIGAND BINDING; REVIEW; TARGET CELL DESTRUCTION;

EID: 65549140215     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520610909030304     Document Type: Review

References (193)

1. http://www.who.int/mediacentre/factsheets/fs297/en/
2. Kratz, F; Müller, I.A; Ryppa, C; Warnecke, A. Prodrug strategies in anticancer chemotherapy. ChemMedChem, 2008, 3(1), 20-53.
3. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Järvinen, T.; Savolainen, J. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov., 2008, 7(3), 255-270.
4. Shukla, G.S.; Krag, D.N. Selective delivery of therapeutic agents for the diagnosis and treatment of cancer. Expert Opin. Biol. Ther., 2006, 6(1), 39-54.
5. de Albuquerque, S.A.T.; Chung, M.C.; Castro, L.F.; Carvalho, G.R.V.; Ferriera, E.I. Advances in prodrug design. Mini Rev. Med. Chem., 2005, 5(10), 893-914.
6. Yoon, K.J.; Potter, P.M.; Danks, M.K. Development of prodrugs for enzyme-mediated, tumor-selective therapy. Curr. Med. Chem. Anti-Cancer Agents, 2005, 5(2), 107-113.
7. Jiang, T.; Olsen, E.S.; Quyen, T.N.; Roy, M.; Jennings, P.A.; Tsien, R.Y. Tumor imaging by means of proteolytic activation of cell-penetrating peptides, Proc. Natl. Acad. Sci. USA, 2004, 101(51), 17867-17872.
8. Han, H.K.; Amidon, G.L. Targeted prodrug design to optimize drug delivery. AAPS Pharm Sci, 2000, 2(1), E6.
9. Chari, R.V.J. Targeted delivery of chemotherapeutics: tumour-activated prodrug therapy. Adv. Drug Deliv. Rev., 1998, 31(1-2), 89-104.
10. Hamann, P.R.; Hinman, L.M.; Hollander, I.; Beyer, C.F.; Lindh, D.; Holcomb, R., Hallett W.; Tsou, H.R.; Upeslacis, J.; Shochat, D.; Mountain, A.; Flowers, D.A.; Bernstein, I. Gemtuzumab Ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem., 2002, 13(1), 47-58.
11. Sievers, E.L.; Appelbaum, F.R.; Spielberger, R.T.; Forman, S.J.; Flowers, D.; Smith, F.O.; Shannon-Dorcy, K.; Berger, M.S.; Bernstein, I.D. Selective ablation of acute myeloid leukemia using anti-body-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood, 1999, 93(11), 3678-3684.
12. Prescott, D.M.; Charles, H.C.; Poulson, J.M.; Page, R.L.; Thrall, D.E.; Vujaskovic, Z.; Dewhirst, M.W. The relationship between intracellular and extracellular pH in spontaneous canine tumors. Canc. Res., 2000, 6(6), 2501-2505.
13. Kratz, F.; Beyer, U.; Schütte, M.T. Drug-polymer conjugates containing acid-cleavable bonds. Crit. Rev. Ther. Drug Carrier Syst., 1999, 16(3), 245-288.
14. Vol'pin, M.; Levitin, E.; Osinski, S. New course in the search for antitumor agents: the use of pH-dependent sources of reactive radicals. Angew. Chem. Int. Ed., 1996, 35(20), 2395-2396.
15. Tietze, L.F.; Beller, M. Development of selective anticancer agents. Synthesis of acetal β-glucosides from cytotoxic alcohols. Liebigs Ann. Chem. 1990, 6, 587-591.
16. Tietze, L.F.; Beller, M.; Fischer, R.; Lögers, M.; Jähde, E; Glüsenkamp, K. Rajewsky, M.F. Development of custom-made, acid-catalytically activatable cytostatics for selective tumor therapy. Angew. Chem. Int. Ed. Engl., 1990, 29(7), 782-783.
17. Tannock, I.F.; Rotin, D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res., 1989, 49(16), 4373-4384.
18. Tietze, L.F.; Fischer, R. Stereoselective synthesis of β-glucosides with 1,1′-diacetal structure. Angew. Chem. Int. Ed. Engl. 1981, 20(11), 696-970.
19. Warburg, O. On respiratory impairment in cancer cells. Science, 1956, 124(3215), 269-270.
20. Bagshawe, K.D. Antibody-directed enzyme prodrug therapy (ADEPT) of cancer. Expert Rev. Anticancer Ther., 2006, 6(10), 1421-1431.
21. Sharma, S.K.; Bagshawe, K.D.; Begent, R.H. Advances in anti-body-directed enzyme prodrug therapy. Curr. Opin. Investig. Drugs, 2005, 6(6), 611-615.
22. Tietze, L.F.; Feuerstein, T. Enzyme and proton-activated prodrugs for a selective cancer therapy. Curr. Pharm. Des., 2003, 9(26), 2155-2175.
23. Tietze, L.F.; Feuerstein, T. Highly selective compounds for the antibody-directed enzyme prodrug therapy of cancer. Aust. J. Chem., 2003, 56(9), 841-854.
24. Nishi, Y. Enzyme/abzyme prodrug activation systems: potential use in clinical oncology. Curr. Pharm. Des., 2003, 9(26), 2113-2130.
25. Jung, M. Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy. Mini Rev. Med. Chem., 2001, 1(4), 399-407.
26. Xu, G.; McLeod, H.L. Strategies for enzyme/prodrug cancer therapy. Clin. Cancer Res., 2001, 7(11), 3314-3324.
27. Senter, P.D.; Springer, C.J. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv. Drug Deliv. Rev., 2001, 53(3), 247-264.
28. Syrigos, K.N.; Epenetos, A.A. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Anticancer Res., 1999, 19(1A), 605-613.
29. Senter, P.D.; Saulnier, M.G.; Schreiber, G.J.; Hirschberg, D.L.; Brown, J.P.; Hellström, I.; Hellström, K.E. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc. Natl. Acad. Sci. USA, 1988, 85(13), 4842-4846.
30. Bagshawe, K.D. Antibody directed enzymes revive anti-cancer prodrugs concept. Br. J. Cancer, 1987, 56(5), 531-532.
31. Cheng, T.L.; Wei, S.L.; Chern, B.M.; Wu, M.F.; Liu, P.W.; Roffler, S.R. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug. Br. J. Cancer, 1999, 79(9-10), 1378-1385.
32. Pessah, N.; Reznik, M.; Shamis, M.; Yantiri, F.; Xin, H.; Bowdish, K.; Shomron, N.; Ast, G.; Shabat, D. Bioactivation of carbamate-based 20(S)-camptothecin prodrugs. Bioorg. Med. Chem., 2004, 12(8), 1859-1866.
33. Deckert, P.M.; Bornmann, W.G.; Ritter, G.; Williams, C. Jr.; Franke, J.; Keilholz, U.; Thiel, E.; Old, L.J.; Bertino, J.R.; Welts, S. Specific tumour localisation of a huA33 antibody: carboxypeptidase A conjugate and activation of methotrexate-phenylalanine. Int. J. Oncol., 2004, 24(5), 1289-1295.
34. Niculescu-Duvaz, I.; Friedlos, F.; Niculescu-Duvaz, D.; Davies, L.; Springer, C.J. Prodrugs for antibody-and gene-directed enzyme prodrug therapies (ADEPT and GDEPT). Anticancer Drug Des., 1999, 14(6), 517-538.
35. Madec-Lougerstay, R.; Florent, J.-C.; Monneret, C. Synthesis of self-immolative glucuronide spacers based on aminomethylcarbamate. Application to 5-fluorouracil prodrugs for antibody-directed enzyme prodrug therapy. J. Chem. Soc. Perkin Trans. 1, 1999, 10, 1369-1375.
36. Leu, Y.L.; Roffler, S.R.; Chern, J.W. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer pro-drug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). J. Med. Chem., 1999, 42(18), 3623-3628.
37. Florent, J.C.; Dong, X.; Gaudel, G.; Mitaku, S.; Monneret, C.; Gesson, J.P.; Jacquesy, J.C.; Mondon, M.; Renoux, B.; Andrianomenjanahary, S.; Michel, S.; Koch, M.; Tillequin, F.; Gerken, M.; Czech, J.; Straub, R.; Bosslet, K. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J. Med. Chem., 1998, 41(19), 3572-3581.
38. Smith, G.K.; Banks, S.; Blumenkopf, T.A.; Cory, M.; Humphreys, J.; Laethem, R.M.; Miller, J.; Moxham, C.P.; Mullin, R.; Ray, P.H.; Walton, L.M.; Wolfe, L.A. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate. J. Biol. Chem., 1997, 272(25), 15804-15816.
39. Smal, M.A.; Dong, Z.; Cheung, H.T.; Asano, Y.; Escoffier, L.; Costello, M.; Tattersall, M.H. Activation and cytotoxicity of 2-α-aminoacyl prodrugs of methotrexate. Biochem. Pharmacol., 1995, 49(4), 567-574.
40. Rodrigues, M.L.; Carter, P.; Wirth, C.; Mullins, S.; Lee, A.; Black-burn, B.K. Synthesis and β-lactamase-mediated activation of a cephalosporin-taxol prodrug. Chem. Biol., 1995, 2(4), 223-227.
41. Svensson, H.P.; Vrudhula, V.M.; Emswiler, J.E.; MacMaster, J.F.; Cosand, W.L.; Senter, P.D.; Wallace, P.M. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody β-lactamase conjugates. Cancer Res., 1995, 55(11), 2357-2365.
42. Kerr, D.E.; Schreiber, G.J.; Vrudhula, V.M.; Svensson, H.P.; Hellström, I.; Hellström, K.E.; Senter, P.D. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody β-lactamase conjugates in combination with anticancer prodrugs. Cancer Res., 1995, 55(16), 3558-3563.
43. Blakey, D.C.; Valcaccia, B.E.; East, S.; Wright, A.F.; Boyle, F.T.; Springer, C.J.; Burke, P.J.; Melton, R.G.; Bagshawe, K.D. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug. Cell Biophys., 1993, 22(1-3), 1-8.
44. Martin, D.G.; Biles, C.; Gerpheide, S.A.; Hanka, L.J.; Krueger, W.C.; McGovren, J. P.; Mizsak, S.A.; Neil, G.L.; Stewart, J.C.; Visser, J. CC-1065 (NSC 298223), a potent new antitumor agent improved production and isolation, characterization and antitumor activity. J. Antibiot., 1981, 34(9), 1119-1125.
45. Ichimura, M.; Ogawa, T.; Takahashi, K.; Kobayashi, E.; Kawamoto, I.; Yasuzawa, T.; Takahashi, I.; Nakano, H. Duocarmycin, a new antitumor antibiotic from streptomyces sp. J. Antibiot., 1990, 43(8), 1037-1038.
46. Igarashi, Y.; Futamata, K.; Fujita, T.; Sekine, A.; Senda, H.; Naoki, H.; Furumai, T. Yatakemycin, a novel antifungal antibiotic produced by Streptomyces sp. TP-A0356. J. Antibiot., 2003, 56(2), 107-113.
47. Baraldi, P.G.; Bovero, A.; Fruttarolo, F.; Preti, D.; Tabrizi, M.A.; Pavani, M.G.; Romagnoli, R. DNA minor groove binders as potential antitumor and antimicrobial agents. Med. Res. Rev., 2004, 24(4), 475-528.
48. Denny, W.A. Tumor-activated prodrugs - a new approach to cancer therapy. Cancer Investig., 2004, 22(4), 604-619.
49. Cacciari, B.; Romagnoli, R.; Baraldi, P.G.; Da Ros, T.; Spalluto, G. CC-1065 and the duocarmycins: recent developments. Exp. Opin. Ther. Pat., 2000, 10(12), 1853-1871.
50. Nagamura, S.; Asai, A.; Kobayashi, E.; Gomi, K.; Saito, H. Studies on duocarmycin SA and its derivatives. Bioorg. Med. Chem., 1997, 5(3), 623-630.
51. McGovern, J.P.; Clarke, G.L.; Pratt, E.A.; deKoning, T.F. Preliminary toxicity studies with the DNA-binding antibiotic CC-1065. J. Antibiot., 1984, 37(1), 63-70.
52. Sato A.; McNulty, L.; Cox, K.; Kim, S.; Scott, A.; Daniell, K.; Summerville, K.; Price, C.; Hudson, S.; Kiakos, K.; Hartley, J.A.; Asao, T.; Lee, M. A class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065. J. Med. Chem., 2005, 48(11), 3903-3918.
53. Denny, W.A. DNA minor groove alkylating agents. Curr. Med. Chem., 2001, 8(5), 533-544.
54. Reddy, B.S.P., Sharma, S.K., Lown, J.P.W. Recent developments in sequence selective minor groove DNA effectors. Curr. Med. Chem., 2001, 8(5), 475-508.
55. Burris, H.A.; Dieras, V.C.; Tunca, M.; Earhart, R.H.; Echardt, J.R.; Rodriguez, G.I.; Shaffer, D.S.; Fields, S.M.; Campbell, E.; Scaaf, L.; Kasunic, D.; Von Hoff, D.D. Phase I study with the DNA sequence-specific agent adozelesin. Anticancer Drugs, 1997, 8(6), 588-596.
56. Foster, B.J.; LoRusso, P.M.; Poplin, E.; Zalupski, M.; Valdivieso, M.; Wozniak, A.; Flaherty, L.; Kasunic, D.A.; Earhart, R.H.; Baker, L.H. Phase I trial of adozelesin using the treatment schedule of daily × 5 every 3 weeks. Invest. N. Drugs, 1996, 13(4), 321-326.
57. Hightower, R.D.; Sevin, B.-U.; Perras, J.P.; Untch, M.; Angioli, R.; Averette, H. Comparison of U-73,975 and cisplatin cytotoxicity in fresh cervical and ovarian carcinoma specimens with the ATP-chemosensitivity assay. Gynecol. Oncol., 1992, 47(2), 186-190.
58. van Tellingen, O.; Punt, C.J.A.; Awada, A.; Wagener, D.J.T.; Piccart, M.J.; Groot, Y.; Schaaf, L.J.; Henrar, R.E.C.; Nooijen, W.J.; Beijnen, J.H. A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study. Cancer Chemother. Pharmacol., 1998, 41(5), 377-384.
59. Wolff, I.; Bench, K.; Beijnen, J.H.; Bruntsch, U.; Cavalli, F.; de Jong, J; Groot, Y.; van Tellingen, O.; Wanders, J.; Sessa, C. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days. Clin. Cancer Res., 1996, 2(10), 1717-1723.
60. Li, L.H.; deKoning, T.F.; Kelly, R.C.; Krueger, W.C.; McGovren, J.P.; Padbury, G.E.; Petzold, G.L.; Wallace, T.L.; Ouding, R.J.; Prairie, M.D.; Gebhard, I. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. Cancer Res., 1992, 52(18), 4904-4913.
61. Schwartz, G.H.; Patnaik, A.; Hammond, L.A.; Rizzo, J.; Berg, K.; Von Hoff, D.D.; Rowinsky, E.K. A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies. Ann. Oncol., 2003, 14(5), 775-782.
62. Pitot, H.C.; Reid, J.M.; Sloan, J.A.; Ames, M.M.; Adjei, A.A.; Rubin, J.; Bagniewski, P.G.; Atherton, P.; Rayson, D.; Goldberg, R.M.; Ehrlichman, C. A phase I study of bizelesin (NSC 615291) in patients with advanced solid tumors. Clin. Cancer Res., 2002, 8(3), 712-717.
63. Pitot, H.C.; Erlichman, C.; Reid, J.M.; Sloan, J.A.; Ames, M.M.; Bagniewski, P.G.; Atherton-Skaff, P.; Adjei, A.A.; Rubin, J.; Rayson, D.; Goldberg, R.M. A phase I study of bizelesin (NSC 615291) in solid tumors. Proc. Am. Assoc. Cancer Res., 1999, 40, 91-92.
64. Markovic, S.N.; Suman, V.J.; Vokov, A.M.; Fitch, T.R.; Hillman, D.W.; Adjei, A.A.; Alberts, S.R.; Kaur, J.S.; Braich, T.A.; Leitch, J.M.; Creagan, E.T. Phase II trial of KW2189 in patients with advanced malignant melanoma. Am. J. Clin. Oncol., 2002, 25(3), 308-312.
65. Rubin, J.; Alberts, S.; Suman, V.; Pitot, H.; Greene, M.; Camoriano, J. Phase II trial of KW2189 in patients with advanced hepatocellular carcinoma. Proc. Am. Soc. Clin. Oncol., 2000, 19, abstr. 1198.
66. Asai, A.; Nagamura, S.; Kobayashi, E.; Gomi, K.; Saito, H. Synthesis and antitumor activity of water-soluble duocarmycin B1 prodrugs. Bioorg. Med. Chem. Lett., 1999, 9(20), 2995-2998.
67. Alberts, S.R.; Erlichman, C.; Reid, J.M.; Sloan, J.A.; Ames, M.M.; Richardson, R.L.; Goldberg, R.M. A phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks. Clin. Canc. Res., 1998, 4(9), 2111-2117.
68. Ohba, K.; Watabe, H.; Sasaki, T.; Takeuchi, Y.; Kodama, Y.; Nakazawa, T.; Yamamoto, H.; Shomura, T.; Sezaki, M., Kondo, S. Pyrindamycins A and B, new antitumor antibiotics. J Antibiot., 1988, 41(10), 1515-1519.
69. Nagamura, S.; Saito H. Antitumor antibiotics: duocarmycins. Chem. Heterocycl. Comp., 1998, 34(12), 1386-1405.
70. Nagamura, S.; Kobayashi, E.; Gomi, K.; Saito, H. Studies on the active metabolite (DU-86) of KW-2189, a novel derivative of duocarmycin. Bioorg. Med. Chem. Lett., 1996, 6(17), 2147-2150.
71. Nagamura, S.; Kobayashi, E.; Gomi, K.; Saito, H. Synthesis and antitumor activity of duocarmycin derivatives: A-ring pyrrole analogues of duocarmycin B2. Bioorg. Med. Chem., 1996, 4(8), 1379-1391.
72. Asai, A.; Nagamura, S.; Saito, S. A novel property of duocarmycin and its analogues for covalent reaction with DNA. J. Am. Chem. Soc., 1994, 116(10), 4171-4177.
73. Kobayashi, E.; Okamoto, A.; Asada, M.; Okabe, M.; Nagamura, S.; Asai, A.; Saito, H.; Gomi, K.; Hirata, T. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors. Cancer Res., 1994, 54(9), 2404-2410.
74. Lee, C.S.; Gibson, N.W. DNA damage and differential cytotoxicity produced in human carcinoma cells by CC-1065 analogues, U-73,975 and U-77,779. Cancer Res., 1991, 51(24), 6586-6591.
75. Teicher, B.A.; Frei, E. Development of alkylating agent-resistant human tumor cell lines. Cancer Chemother. Pharmacol., 1988, 21(4), 292-298.
76. Denny, W.A. DNA minor groove alkylators. Front. Med. Chem., 2004, 1(14), 581-594.
77. Searcey, M. Duocarmycins - natures prodrugs? Curr. Pharm. Des., 2002, 8(15), 1375-1389.
78. Boger, D.L.; Johnson, D. S. CC-1065 and the duocarmycins: understanding their biological function through mechanistic studies. Angew. Chem., Int. Ed., 1996, 35(13-14), 1438-1474.
79. Tietze, L.F.; Schuster, H.; Krewer, B.; Schuberth, I. Synthesis and biological studies of different duocarmycin based glycosidic prodrugs for their use in the antibody-directed enzyme prodrug therapy. J. Med. Chem., 2008, (in press).
80. Milbank, J.B.J.; Tercel, M.; Atwell, G.J.; Wilson, W.R.; Hogg, A.; Denny, W.A. Synthesis of 1-substituted 3-(chloromethyl)-6-aminoindoline (6-amino-seco-CI) DNA minor groove alkylating agents and structure-activity relationships for their cytotoxicity. J. Med. Chem., 1999, 42(4), 649-658.
81. Zientkowska, M. Evaluierung des Antibody Directed Enzyme Prodrug Therapy-Konzeptes im Mammakarzinom- und Lymphom-Mausmodell, Göttingen, 2007.
82. Tietze, L.F.; Major, F.; Schuberth, I.; Spiegl, D.A.; Krewer, B.; Maksimenka, K.; Bringmann, G.; Magull, J. Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins. Chem. Eur. J., 2007, 13(16), 4396-4409.
83. Tietze, L.F.; Major, F.; Schuberth, I. Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy. Angew. Chem., 2006, 118(39), 6724-6727
84. Tietze, L.F.; Major, F.; Schuberth, I. Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy. Angew. Chem., Int. Ed., 2006, 45(39), 6574-6577.
85. Bosman, H.B.; Hall, T.C. Enzyme activity in invasive tumors of human breast and colon. Proc. Natl. Acad. Sci. USA, 1974, 71(5), 1833-1837.
86. Tietze, L.F.; Schuster, H.J.; Hampel, S. M.; Rühl, S.; Pfoh, R. Enantio- and diastereoselective synthesis of duocarmycin-based prodrugs for a selective treatment of cancer by epoxide opening. Chem. Eur. J., 2008, 14(3), 895-901.
87. Tietze, L.F.; Major, F. Synthesis of new water-soluble DNA-binding subunits for analogues of the cytotoxic antibiotic CC-1065 and their prodrugs. Eur. J. Org. Chem., 2006, 10, 2314-2321.
88. Parrish, J.P.; Kastrinsky, D.B.; Stauffer, F.; Hedrick, M.P.; Hwang, I.; Boger, D.L. Establishment of substituent effects in the DNA binding subunit of CBI analogues of the duocarmycins and CC-1065. Bioorg. Med. Chem., 2003, 11(17), 3815-3838.
89. Boger, D.L.; Bollinger, B.; Johnson, D.S. Examination of the role of the duocarmycin SA methoxy substituents: identification of the minimum, fully potent DNA binding subunit. Bioorg. Med. Chem. Lett., 1996, 6(18), 2207-2210.
90. Tietze, L.F.; Krewer, B.; Frauendorf, H.; Major, F.; Schuberth, I. Investigation of reactivity and selectivity of DNA-alkylating duocarmycin analogues by high-resolution mass spectrometry. Angew. Chem., 2006, 118(39), 6720-6724
91. Tietze, L.F.; Krewer, B.; Frauendorf, H.; Major, F.; Schuberth, I. Investigation of reactivity and selectivity of DNA-alkylating duocarmycin analogues by high-resolution mass spectrometry. Angew. Chem., Int. Ed., 2006, 45(39), 6570-6574.
92. Tietze, L.F.; von Hof, J.M.; Krewer, B.; Müller, M.; Major, F.; Schuster, H.J.; Schuberth, I.; Alves, F. Asymmetric synthesis and biological evaluation of new glycosidic prodrugs for a selective cancer therapy. ChemMedChem, 2008, 3(12), 1946-1955.
93. Hamann, P.R. Monoclonal antibody-drug conjugates. Expert Opin. Ther. Pat., 2005, 15(9), 1087-1103.
94. Wang, Y.; Yuan, H.; Wright, S.C.; Wang, H.; Larrick, J.W. Synthesis and preliminary cytotoxicity study of glucuronide derivatives of CC-1065 analogues. Bioorg. Med. Chem., 2003, 11(7), 1569-1575.
95. Wang, Y.; Wright, S.C.; Larrick, J.W. DNA-binding indole derivatives, their prodrugs and immunoconjugates. United States Patent, Number 5843937, 1998.
96. Wang, Y.; Yuan, H.; Wright, S.C.; Wang, H.; Larrick, J.W. Synthesis and preliminary cytotoxicity study of a cephalosporin-CC-1065 analogue prodrug. BMC Chem. Biol., 2001, 1:4.
97. Jungheim, L.N; Shepherd, T.A.; Kling, J. K. Synthesis of a cephalosporin-doxorubicin antitumor prodrug: a substrate for an antibody-targeted enzyme. Heterocycles, 1993, 35(1), 339-348.
98. Wright, S.C.; Schellenberger, U.; Wang, H.; Wang, Y.; Kinder, D.H. Chemotherapeutic drug activation of the AP24 protease in apoptosis: requirement for caspase 3-like-proteases. Biochem. Biophys. Res. Commun., 1998, 245(3), 797-803.
99. Kovtun, Y.V.; Audette, C.A.; Ye, Y.; Xie, H.; Ruberti, M.F.; Phinney, S.J.; Leece, B.A.; Chittenden, T.; Blättler, W.A.; Goldmacher, V.S. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the targeted antigen. Cancer Res., 2006, 66(6), 3214-3221.
100. Lambert, J.M. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol., 2005, 5(5), 543-549.
101. Jeffrey, S.C.; Torgov, M.Y.; Andreyka, J.B.; Boddington, L.; Cerveny, C.G.; Denny, W.A.; Gordon, K.A.; Gustin, D.; Haugen, J.; Kline, T.; Nguyen, M.T.; Senter, P.D. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates. J. Med. Chem., 2004, 47(6), 1344-1358.
102. Suzawa, T.; Nagamura, S.; Saito, H.; Ohta, S.; Hanai, N.; Yamasaki, M. Synthesis of a novel duocarmycin derivative DU-257 and its application to immunoconjugate using poly(ethylene glycol)-dipeptidyl linker capable of tumor specific activation. Bioorg. Med. Chem., 2000, 8(8), 2175-2184.
103. Greco, O.; Dachs, G.U. Gene-directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J. Cell. Physiol., 2001, 187(1), 22-36.
104. Denny, W.A. prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J. Biomed. Biotech., 2003, 1(1), 48-70.
105. Hay, M.P.; Sykes, B.M.; Denny, W.A.; Wilson, W.R. A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[5,6,7-trimethoxyindol-2-yl)carbonyl]- 1,2-dihydro-3H-benz[e]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT. Bioorg. Med. Chem. Lett., 1999, 9(6), 2237-2242.
106. Hay, M.P.; Atwell, G.J.; Wilson, W.R.; Pullen, S.M.; Denny, W.A. Structure-activity relationship for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjugation with E. coli nitroreductase. J. Med. Chem., 2003, 46(12), 2456-2466.
107. De Groot, F.M.H.; Damen, E.W.P.; Scheeren, H.W. Anticancer prodrugs for application in monotherapy targeting hypoxia, tumor-associated enzymes, and receptors. Curr. Med. Chem., 2001, 8(9), 1093-1122.
108. Bosslet, K; Straub, R.; Blumrich, M; Czech, J.; Gerken, M.; Sperker, B.; Kroemer, H. K.; Gesson, J.-P.; Koch, M.; Monneret, C. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res., 1998, 58(6), 1195-1201.
109. Ganesh, T. Improved biochemical strategies for targeted delivery of taxoids. Bioorg. Med.Chem., 2007, 15(11), 3597-3623.
110. Devalapally, H.; Navath, R.S.; Yenamandra, V.; Akkinepally, R.R.; Devarakonda, R.K. β-galactoside prodrugs of doxorubicin for application in antibody directed enzyme prodrug therapy/prodrug mono therapy. Arch. Pharm. Res., 2007, 30(6), 723-732.
111. Alaoui, A.E.; Saha, N.; Schmidt, F.; Monneret, C.; Florent, J.-C. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy. Bioorg. Med. Chem., 2006, 14(14), 5012-5019.
112. Kratz, F.; Warnecke, A.; Schmid, B.; Chung, D.-E.; Gitzel, M. Prodrugs of anthracyclines in cancer chemotherapy. Curr. Med. Chem., 2006, 13(5), 477-523.
113. Schmidt, F.; Monneret, C. Prodrug Monotherapy: synthesis and biological evaluation of an etoposide glucuronide-prodrug. Bioorg. Med. Chem., 2003, 11(10), 2277-2283.
114. Prijovich, Z.M.; Chen, B.M.; Leu, Y.-L.; Chern, J.-W.; Roffler, S.R. Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9 ACG) in mice. Br. J. Cancer, 2002, 86(10), 1634-1638.
115. Denny, W.A. Prodrugs strategies in cancer therapy. Eur. J. Med. Chem., 2001, 36(7-8), 577-595.
116. Bosslet, K.; Czech, J.; Hoffmann, D. A novel one-step tumour-selective prodrug activation system. Tumor Target., 1995, 1(1), 45-50.
117. Connors, T.A.; Whisson, M.E. Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. Nature, 1966, 210(5038), 866-867.
118. Mürdter, T.E.; Friedel, G.; Backmann, J.T.; McClellan, M.; Schick, M.; Gerken, M.; Bosslet, K.; Fritz, P.; Toomes, H.; Kroemer, H.K.; Sperker, B. Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by β-glucuronidase. J. Pharmacol. Exp. Ther., 2002, 301(1), 223-228.
119. Sinhababu, A.; Thakker, D. Prodrugs of anticancer agents. Adv. Drug Deliv. Rev., 1996, 19(2), 241-273.
120. Tietze, L.F.; Seele, R.; Leiting, B.; Krach, T. Stereoselective synthesis of (1-alkoxyalkyl) α- and β-D-glucopyranosiduronates (acetal-glucopyranosiduronates): a new approach to specific cytostatics for the treatment of cancer. Carbohydr. Res., 1988, 180(2), 253-262.
121. Wang, S.-M.; Chern, J.-W.; Yeh, M.-Y.; Ng, J.C.; Tung, E.; Roffler, S.R. Specific activation of glucuronide prodrugs by anti-body-targeted enzyme conjugates for cancer therapy. Cancer Res., 1992, 52(16), 4484-4491.
122. Alaoui, A.E.; Schmidt, F.; Monneret, C.; Florent, J.-C. Protecting groups for glucuronic acid: application to the synthesis of new paclitaxel (Taxol) derivatives. J. Org. Chem., 2006, 71(26), 9628-9636.
123. Bouvier, E.; Thirot, S.; Schmidt, F.; Monneret, C. First enzymatic activated Taxotere prodrugs designed for ADEPT and PMT. Bioorg. Med. Chem., 2004, 12(5), 969-977.
124. Bouvier, E.; Thirot, S.; Schmidt, F.; Monneret, C. A new paclitaxel prodrug for use in ADEPT strategy. Org. Biomol. Chem., 2003, 1(19), 3343-3352.
125. Chen, X.; Wu, B.; Wang, P.G. Glucuronides in anti-cancer therapy. Curr. Med. Chem. Anti-Cancer Agents, 2003, 3(2), 139-150.
126. Houba, P.H. J.; Boven, E.; van der Muileman, I.H.; Leenders, R.G.G.; Scheeren, J.W.; Pinedo, H.M.; Haisma, H.J. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody β-glucuronidase conjugate. Int. J. Cancer, 2001, 91(4), 550-554.
127. Gosh, A.K.; Farquhar, D.A methyl glucuronate prodrug of phosphorodiamidic mustard. Tetrahedron Lett., 1997, 38(51), 8795-8798.
128. de Bont, D.B.A.; Leenders, R.G.G.; Haisma, H.J.; van der Meulen-Muileman, I.; Scheeren, H.W. Synthesis and biological activity of β-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT. Bioorg. Med. Chem., 1997, 5(2), 405-414.
129. Tietze, L.F.; Schuster, H.J.; Schmuck, K.; Schuberth, I.; Alves, F. Duocarmycin-based prodrugs for cancer prodrug monotherapy. Bioorg. Med. Chem., 2008, 16(12), 6312-6318.
130. de Graaf, M.; Nevailainen, T.J.; Scheeren, H.W.; Pinedo, H.M.; Haisma, H.; Boven, E. A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy. Biochem. Pharmacol., 2004, 68(11), 2273-2281.
131. Papot, S.; Combaud, D.; Gesson, J.P. A new spacer group derived from arylmalonaldehydes for glucuronylated prodrugs. Bioorg. Med. Chem. Lett., 1998, 8(4), 2545-2548.
132. Reubi, J.C.; Mäcke, H.R.; Krenning, E.P. Candidates for peptide receptor radiotherapy today and in the future. J. Nucl. Med., 2005, 46(1), 67S-75S.
133. Dyba, M.; Tarasova, N.I.; Michejda, C.J. Small molecule toxins targeting tumor receptors. Curr. Pharm. Des., 2004, 10(19), 2311-2334.
134. Reubi, J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev., 2003, 24(4), 389-427.
135. Reubi, J.C.; Waser, B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med., 2003, 30(5), 781-793.
136. Langer, M.; Beck-Sickinger, A.G. Peptides as carrier for tumor diagnosis and treatment. Curr. Med. Chem., 2001, 1(1), 71-93.
137. Beck-Sickinger, A.G.; Khan, I.U. Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals. Anti-Cancer Agents Med. Chem., 2008, 8(2), 186-199.
138. 99mTc-labeled minigastrin analogs. J. Nucl. Med., 2005, 46(10), 1727-1736.
139. Béhé, M.; Behr, T.M. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers (Peptide Science), 2002, 66(6), 399-418.
140. Schmidt, B.F.; Hernandez, L.; Rouzer, C.; Czerwinski, G.; Chmurny, G.; Michejda, C.J. Peptide-Linked 1,3-Dialkyl-3-acyltriazenes: gastrin receptor directed antineo-plastic alkylating agents. J. Med. Chem., 1994, 37(22), 3812-3818.
141. Czerwinski, G.; Tarasova, N.I.; Michejda, C.J. Cytotoxic agents directed to peptide hormone receptors: Defining the requirements for a successful drug. Proc. Natl. Acad. Sci. USA, 1998, 95(20), 11520-11525.
142. Buchholz, S.; Keller, G.; Schally, A.V.; Halmos, G.; Hohla, F.; Heinrich, E.; Koester, F.; Baker, B.; Engel, J.B. Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. Proc. Natl.Acad. Sci. USA, 2006, 103(27), 10403-10407.
143. Nagy, A.; Schally, A.V. Minireview. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol. Reprod., 2005, 73(5), 851-859.
144. Engel, J.B.; Keller, G.; Schally, A.V.; Halmos, G.; Hammann, B.; Nagy, A. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215. Clin. Cancer Res., 2005, 11(6), 2408-2415.
145. Szepesházi, K.; Schally, A.V.; Halmos, G.; Armatis, P.; Hebert, F.; Sun, B.; Feil, A.; Kiaris, H.; Nagy, A. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. Cancer Res., 2002, 62(3), 781-788.
146. Langer, M.; Kratz, F.; Rothen-Rutishauser, B.; Wunderli-Allenspach, H.; Beck-Sickinger, A.G. Novel peptide conjugates for tumor-specific chemotherapy. J. Med. Chem., 2001, 44(9), 1341-1348.
147. Nagy, A.; Schally, A.V.; Armatis, P.; Szepesházi, K.; Halmos, G.; Kovács, M.; Zarandi, M.; Groot, K.; Miyazaki, M.; Jungwirth, A.; Horvath, J. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc. Natl. Acad. Sci. USA, 1996, 93(14), 7269-7273.
148. Morley, J.S.; Tracy, H.J.; Gregory, R.A. Structure-function relationships in the active C-terminal tetrapeptide sequence of gastrin. Nature, 1965, 207(5004), 1356-1359.
149. Tracy, H.J.; Gregory, R.A. The antral hormone gastrin: physiological properties of a series of synthetic peptides structurally related to gastrin I. Nature, 1964, 204(4948), 935-938.
150. Tietze, L.F.; Panknin, O.; Major, F.; Krewer, B. Synthesis of a novel pentagastrin-drug conjugate for a targeted tumor therapy. Chem. Eur. J., 2008, 14(9), 2811-2818.
151. Harris, L.A. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2002, 2(1), 38-47.
152. Tanabe, K.; Zhang, Z.; Ito, T.; hatta, H.; Sei-ichi, N. Current molecular design of intelligent drugs and imaging probes targeting tumor-specific microenvironments. Org. Biomol. Chem., 2007, 5(23), 3745-3757.
153. Gong, J.; Vaidyanathan, V.G.; Yu, X.; Kensler, T. W.; Peterson, L. A.; Sturla, S. J. Depurinating acylfulvene-DNA adducts: characterizing cellular chemical reactions of a selective antitumor agent J. Am. Chem. Soc., 2007, 129(7), 2101-2111.
154. Denny, W.A. Hypoxia-activated anticancer drugs. Exp. Opin. Ther. Pat., 2005, 15(6), 635-646.
155. Denny, W.A. The design of drugs that target tumour hypoxia. Aust. J. Chem., 2004, 57(9), 821-828.
156. Liu, B.; Hu, L. 5′-(2-Nitrophenylalkanoyl)-2′-deoxy-5-fluorouridines as potential prodrugs of FUDR for reductive activation. Bioorg. Med. Chem., 2003, 11(18), 3889-3899.
157. Skibo, E. B.; Xing, C.; Dorr, R. T. Aziridinyl quinone anticancer agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity. J. Med. Chem., 2001, 44(22), 3545-3562.
158. Atwell, G.J.; Tercel, M.; Boyd, M.; Wilson, W.R.; Denny, W.A. Synthesis and cytotoxicity of 5-Amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]- 1,2-dihydro-3H-benz[e]indole (Amino-seco-CBI-TMI) and related 5-alkylamino analogues: new DNA minor groove alkylating agents. J. Org. Chem., 1998, 63(25), 9414-9420.
159. Atwell, G.J.; Milbank, J.B.J.; Wilson, W.R.; Hogg, A.; Denny, W.A. 5-Amino-1-(chloromethyl)-1,2-dihydro-3H-benz [e]indoles: relationships between structure and cytotoxicity for analogues bearing different DNA minor groove binding subunits. J. Med. Chem., 1999, 42(17), 3400-3411.
160. Gieseg, M.A.; Matejovic, J.; Denny, W.A. Comparison of the patterns of DNA alkylation by phenol and amino seco-CBI-TMI compounds: use of a PCR method for the facile preparation of single end-labelled double-stranded DNA. Anticancer Drug Des., 1999, 14(8), 77-84.
161. Jin, W.; Trzupek, J.D.; Rayl, T.J.; Broward, M.A.; Vielhauer, G.A.;
162. Denny, W.A.; Wilson, W.R.; Ware, D.C.; Atwell, G.J.; Milbank, J. B. J.; Stevenson, R. J. Anti-cancer 2,3-dihydro-1H-pyrrolo[3,2-f]quinoline complexes of cobalt and chromium. PCT Int. Appl. No. WO0259122 A1, 2002.
163. Wang, Y.; Li, L.; Tian, Z.; Jiang, W.; Larrick, J. W. Synthesis and antitumor activity of CBI-bearing ester and carbamate prodrugs of CC-1065 analogue. Bioorg. Med. Chem., 2006, 14(23), 7854-7861.
164. Wang, Y.; Jiang, J.; Jiang, X.; Cai, S.; Han, H.; Li, L.; Tian, Z.; Jiang, W.; Zhang, Z.; Xiao, Y.; Wright, S.C., Larrick, J. W. Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog. Bioorg. Med. Chem., 2008, 16(13), 6552-6559.
165. Kratz, F.; Beyer, U. Serum proteins as drug carriers of anticancer agents, a review. Drug Deliv., 1998, 5(4), 281-299.
166. Sauer, L.A.; Stayman, J.W.; Dauchy, R.T. Amino acid, glucose, and lactic acid utilization in vivo by rat tumors. Cancer Res., 1982, 42(9), 4090-4097.
167. Buchwald, P. Structure-metabolism relationships, steric effects and the enzymatic hydrolysis of carboxylic esters. Mini Rev. Med. Chem., 2001, 1(1), 101-111.
168. 3H]thymidine incorporation in hepatoma 7288CTC perfused in situ. Br. J. Cancer, 1992, 66(2), 297-303.
169. Sparreboom, A.; Wolff, A.C.; Verweij, J.; Zabelina, Y.; Van Zomeren, D.M.; McIntire, G.L.; Swindell, C.S.; Donehower, R.C.; Baker, S.D. Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. Clin. Cancer Res., 2003, 9(1), 151-159.
170. Bradley, M.O.; Webb, N.L.; Anthony, F.H.; Devanesan, P.; Witman, P.A.; Hemamalini, S.; Chander, M.C.; Baker, S.D.; He, L.; Horwitz, S.B.; Swindell, C.S. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin. Cancer Res., 2001, 7(10), 3229-3238.
171. Wang, Y.; Li, L.; Jiang, W.; Larrick, J.W. Synthesis and evaluation of a DHA and 10-hydroxycamptothecin conjugate. Bioorg. Med. Chem., 2005, 13(19), 5592-5599.
172. Boger, D.L.; Bollinger, B.; Hertzog, D.L.; Johnson, D.S.; Cai, H.; Mésini, P.; Garbaccio, R.M.; Jin, Q.; Kitos, P.A. Reversed and sandwiched analogs of duocarmycin SA: establishment of the origin of the sequence-selective alkylation of DNA and new insights into the source of catalysis. J. Am. Chem. Soc., 1997, 119(21), 4987-4998.
173. Hurley, L.H.; Needham-VanDevanter, D.R. Covalent binding of antitumor antibiotics in the minor groove of DNA. Mechanism of action of CC-1065 and the pyrrolo(1,4)benzodiazepines. Acc. Chem. Res., 1986, 19(8), 230-237.
174. Hurley, L.H.; Reynolds, V.S.; Swenson, D.H.; Petzold, G.L.; Scahill, T.A. Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity. Sience, 1984, 226(4676), 843-844.
175. Cimino, P.; Bifulco, G.; Riccio, R.; Gomez-Paloma, L.; Barone, V. On the role of stereo-electronic effects in tuning the selectivity and rate of DNA alkylation by duocarmycins. Org. Biomol. Chem., 2006, 4(7), 1242-1251.
176. Tse, W.C.; Boger, D.L. Sequence-selective DNA recognition: natural products and nature's lessons. Chem. Biol., 2004, 11(12), 1607-1617.
177. Wolkenberg, S.E.; Boger, D.L. Mechanisms of in situ activation for DNA-targeting antitumor agents. Chem. Rev., 2002, 102(7), 2477-2496.
178. Boger, D.L.; Garbaccio, R.M. Shape-dependent catalysis: insights into the source of catalysis for the CC-1065 and duocarmycins DNA alkylation reaction. Acc. Chem. Res., 1999, 32(12), 1043-1052.
179. Trzupek, J.D.; Gottesfeld, J.M.; Boger, D.L. Alkylation of duplex DNA in nucleosome core particles by duocarmycin SA and yatakemycin. Nat. Chem. Biol., 2006, 2(2), 79-82.
180. Tichenor, M.S.; MacMillan, K.S.; Trzupek, J.D.; Rayl, T.J.; Hwang, I.; Boger, D.L. Systematic exploration of the structural features of yatakemycin impacting DNA alkylation and biological activity. J. Am. Chem. Soc., 2007, 129(35), 10858-10869.
181. Tichenor, M.S.; Trzupek, J.D.; Kastrinsky, D.B.; Shiga, F.; Hwang, I.; Boger, D.L. Asymmetric total synthesis of (+)- and ent-(-)-yatakemycin and duocarmycin SA: evaluation of yatakemycin key partial structures and its unnatural enantiomer. J. Am. Chem. Soc., 2006, 128(49), 15683-15696.
182. Parrish, J.P.; Kastrinsky, D.B.; Wolkenberg, S.E.; Igarashi, Y.; Boger, D.L. DNA alkylation properties of yatakemycin. J. Am. Chem. Soc., 2003, 125(36), 10971-10976.
183. Shinohara, K.-I.; Bando, T.; Sasaki, S., Sakakibara, Y.; Minoshima, M.; Sugiyama, H. Antitumor activity of sequenze-specific alkylating agents: pyrrole-imidazole CBI conjugates with indole linker. Cancer Sci., 2006, 97(3), 219-225.
184. Woynarowski, J.M.; Beerman, T.A. Effects of bizelesin (U-77,779), a bifunctional alkylating minor groove binder, on replication of genomic and simian virus 40 DNA in BSC-1 cells. Biochim. Biophys. Acta, 1997, 1353(1), 50-60.
185. McHugh, M.M.; Woynarowski, J.M.; Mitchell, M.A.; Gawron, L.S.; Weiland, K.L.; Beerman, T.A. CC-1065 bonding to intracellular and purified SV40 DNA: site specificity and functional effects. Biochemistry, 1994, 33(31), 9158-9168.
186. Bhuyan, N.K.; Newell, K.A.; Crampton, S.L.; Von Hoff, D.D. CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DNA synthesis, and cell survival. Cancer Res., 1982, 42(9), 3532-3537.
187. Nelson, S.M.; Ferguson, L.R.; Denny, W.A. DNA and the chromosome - varied targets for chemotherapy. Cell Chromosome, 2004, 3(2), 1-26.
188. Woynarowski, J.M.; Trevino, A.V.; Rodriguez, K.A.; Hardies, S.C., Benham, C.J. AT-rich islands in genomic DNA as a novel target for AT-specific DNA-reactive antitumor drugs. J. Biol. Chem., 2001, 276(44), 40555-40566.
189. Chiang, S.-Y.; Welch, J.; Rauscher, F.J.; Beerman, T.A. Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA. Biochemistry, 1994, 33(23), 7033-7040.
190. Tichenor, M.S.; MacMillen, K.S.; Stover, J.S.; Wolkenberg, S.E.; Pavani, M.G.; Zanella, L.; Zaid, A.N.; Spalluto, G.; Rayl, T.J.; Hwang, I.; Baraldi, P.G.; Boger, D.L. Rational design, synthesis, and evaluation of key analogues of CC-1065 and the duocarmycins. J. Am. Chem. Soc., 2007, 129(45), 14092-14099.
191. Parrish, J.P.; Hughes, T.V.; Hwang, I.; Boger, D.L. Establishing the parabolic relationship between reactivity and activity for derivatives and analogues of the duocarmycins and CC-1065 alkylation subunits. J. Am. Chem. Soc., 2004, 126(1), 80-81.
192. Colgrave, M.L.; Iannitti-Tito, P.; Wickham, G.; Sheil, M.M. Rapid determination of sequence selectivity and stability of alkylated oligonucleotide adducts by electrospray tandem mass spectrometry. Aust. J. Chem., 2003, 56(5), 401-413.
193. Beck, J.L.; Colgrave, M.L.; Ralph, S.F.; Sheil, M.M. Electrospray Ionization mass spectrometry of oligonucleotide complexes with drugs, metals, and proteins. Mass Spectrom. Rev., 2001, 20(2), 61-87.